Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects

Nanomedicine

Volumn 10, Issue 16, 2015, Pages 2513-2525

  Child, Hannah Winifred ^a   Hernandez, Yulán ^b   Conde, João ^c   Mullin, Margaret ^a   Baptista, Pedro ^d   De La Fuente, Jesus Maria ^b   Berry, Catherine Cecilia ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF ZARAGOZA   (Spain)

^c Massachusetts Institute of Technology   (United States)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

apoptosis; c myc; cell cycle; cell delivery; cell proliferation; gene knockdown; gold nanoparticles; knockdown; nanoparticles; off target effects; proliferation; RNAi; siRNA

Indexed keywords

GOLD NANOPARTICLE; SMALL INTERFERING RNA; GOLD; METAL NANOPARTICLE;

APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CELL CYCLE; CELL PROLIFERATION; DRUG DESIGN; DRUG SYNTHESIS; FEMALE; GENE DELIVERY SYSTEM; GENE OVEREXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HELA CELL LINE; HUMAN; HUMAN CELL; ONCOGENE C MYC; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TOXICITY TESTING; TRANSMISSION ELECTRON MICROSCOPY; WESTERN BLOTTING; CHEMISTRY; GENETICS; POLYMERASE CHAIN REACTION;

APOPTOSIS; CELL CYCLE; GENE KNOCKDOWN TECHNIQUES; GOLD; HELA CELLS; HUMANS; METAL NANOPARTICLES; MICROSCOPY, ELECTRON, TRANSMISSION; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84940557101     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.15.95     Document Type: Article

References (62)

1. Pelengaris S, Khan M. The c-myc oncoprotein as a treatment target in cancer and other disorders of cell growth. Exp. Opin. Therap. Targets. 7(5), 623-642 (2003
2. Aulmann S, Adler N, Rom J., et al. c-myc amplifications in primary breast carcinomas and their local recurrences. J. Clin. Pathol. 59(4), 424-428 (2006
3. Beroukhim R, Mermel CH, Porter D., et al. The landscape of somatic copy-number alteration across human cancers. Nature. 463(7283), 899-905 (2010
4. Borg A, Baldetorp B, Ferno M., et al. c-myc amplification is an independent prognostic factor in postmenopausal breastcnacer. Int. J. Cancer. 51(5), 687-691 (1992
5. Bourhis J, Le MG, Barrois M., et al. Prognostic value of c-myc protooncogene overexpression in early invasive-carcinoma of the cervix. J. Clin. Oncol. 8(11), 1789-1796 (1990
6. Deming SL, Nass SJ, Dickson RB., et al. c-myc amplification in breast cancer: a meta-Analysis of its occurrence and prognostic relevance. Br. J. Cancer. 83(12), 1688-1695 (2000
7. Kozma L, Kiss I, Szakall S., et al. Investigation of c-myc oncogene amplification in colorectal-cancer. Cancer Lett. 81(2), 165-169 (1994
8. Fire A, Xu SQ, Montgomery MK., et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391(6669), 806-811 (1998
9. Ameres SL, Martinez J, Schroeder R. Molecular basis for target RNA recognition and cleavage by human RISC. Cell. 130, 101-112 (2007
10. Rand TA, Ginalski K, Grishin NV., et al. Biochemical identification of Argonaute 2 as the sole protein required for RNA-induced silencing complex activity. Proc. Natl Acad. Sci. USA. 101(40), 14385-14389 (2004
11. Elbashir SM, Harborth J, Lendeckel W., et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 411(6836), 494-498 (2001
12. Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J. Cell. Phys. 220(2), 285-291 (2009
13. Kurreck J. RNA interference: from basic research to therapeutic applications. Angew. Chem. Int. Ed. Engl. 48(8), 1378-1398 (2009
14. Akhtar S, Basu S, Wickstrom E., et al. Interactions of antisense DNA oligonucleotide analogs with phospholipidmembranes (liposomes). Nucleic Acids Res. 19(20), 5551-5559 (1991
15. Wittung P, Kajanus J, Edwards K., et al. Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett. 375(3), 27-29 (1995
16. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Ann. Rev. Med. 56(1), 401-423 (2005
17. Huang C, Li M, Chen CY., et al. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Exp. Opin. Ther. Targets. 12(5), 637-645 (2008
18. Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8(2), 129-138 (2009
19. Juliano R, Alam MR, Dixit V., et al. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res. 36(12), 4158-4171 (2008
20. Song EW, Zhu PC, Lee SK., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 23(6), 709-717 (2005
21. Derfus AM, Chen AA, Min DH., et al. Targeted quantum dot conjugates for siRNA delivery. Bioconjug. Chem. 18, 1391-1396 (2007
22. Paciotti GF, Kingston DGI, Tamarkin L. Colloidal gold nanoparticles: a novel nanoparticle platform for developing multifunctional tumor-Targeted drug delivery vectors. Drug Dev. Res. 67(1), 47-54 (2006
23. Lee JH, Lee K, Moon SH., et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew. Chem. Int. Ed. Engl. 48(23), 4174-4179 (2009
24. Huang X, Jain PK, El-Sayed IH., et al. Gold nanoparticles: interesting optical properties and recent applications in cancer diagnostics and therapy. Nanomedicine. 2(5), 681-693 (2007
25. Sanvicens N, Marco MP. Multifunctional nanoparticles - properties and prospects for their use in human medicine. Trends Biotechnol. 26(8), 425-433 (2008
26. Connor EE, Mwamuka J, Gole A., et al. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. Small. 1(3), 325-327 (2005
27. Lee JS, Green JJ, Love KT., et al. Gold, poly(beta-Amino ester) nanoparticles for small interfering RNA delivery. Nano Lett. 9(6), 2402-2406 (2009
28. Chen PC MS, Oyelere AK. Gold nanoparticles: from nanomedicine to nanosensing. Nanotechnol. Sci. Appl. 1, 45-66 (2008
29. Schwarze SR, Dowdy SF. In vivo protein transduction: intracellular delivery of biologically active proteins, compounds and DNA. Trends Pharm. Sci. 21(2), 45-48 (2000
30. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv. Drug Deliv. Rev. 60(4-5), 530-536 (2008
31. Josephson L, Tung CH, Moore A., et al. Highefficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug. Chem. 10(2), 186-191 (1999
32. Berry CC. Intracellular delivery of nanopartides via the HIV-1 tat peptide. Nanomedicine. 3(3), 357-365 (2008
33. Braun GB, Pallaoro A, Wu GH., et al. Laser-Activated gene silencing via gold nanoshell-siRNA conjugates. ACS Nano. 3(7), 2007-2015 (2009
34. Smith C-AM, de la Fuente J, Pelaz B., et al. The effect of static magnetic fields and tat peptides on cellular and nuclear uptake of magnetic nanoparticles. Biomaterials. 31(15), 4392-4400 (2011
35. Qiu S, Adema CM, Lane T.A computational study of off-Target effects of RNA interference. Nucleic Acids Res. 33(6), 1834-1847 (2005
36. Yamada T, Morishita S. Accelerated off-Target search algorithm for siRNA. Bioinformatics. 21(8), 1316-1324 (2005
37. Mohr SE, Smith JA, Shamu CE., et al. RNAi screening comes of age: improved techniques and complementary approaches. Nat. Rev. Mol. Cell Biol. 15, 591-600 (2014
38. Chen Y, Bathula SR, Yang Q., et al. Targeted nanoparticles deliver siRNA to melanoma. J. Invest. Dermatol. 130(12), 2790-2798 (2010
39. Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth processes in the synthesis of colloidal gold. Discuss. Faraday Soc. 11, 55-75 (1951
40. Frens G. Controlled nucleation for the regulation of the particle size in monodisperse gold suspensions. Nat. Phys. Sci. 241, 20-22 (1973
41. Conde J, Ambrosone A, Sanz V., et al. Design of multifunctional gold nanoparticles for in vitro and in vivo silencing. ACS Nano. 6(9), 8316-8324 (2012
42. Lytton-Jean AKR, Langer R., Anderson DG. Five years of siRNA delivery: spotlight on gold nanoparticles. Small. 7, 1932-1937 (2011
43. Meister A, Anderson ME. Glutathione. Ann. Rev. Biochem. 52, 711-760 (1983
44. Li D, Li G, Guo W, Li P, Wang E, Wang J. Glutathionemediated release of functional plasmid DNA from positively charged quantum dots. Biomaterials. 29, 2776-2782 (2008
45. Han G, Chari NS, Verma A, Hong R, Martin CT, Rotello VM. Controlled recovery of the transcription of nanoparticle-bound DNA by intracellular concentrations of glutathione. Bioconjug. Chem. 16, 1356-1359 (2005
46. Hong R, Han G, Fernández JM., et al. Glutathione-mediated delivery and release using monolayer protected nanoparticle carriers. J. Am. Chem. Soc. 128, 1078-1079 (2006
47. Chompoosor A, Han G, Rotello VM. Charge dependence of ligand release and monolayer stability of gold nanoparticles by biogenic thiols. Bioconjug. Chem. 19, 1342-1345 (2008
48. Qian S, Zhong X, Yu L., et al. HIV-1 TAT RNA silencing suppressor activity is conserved across kingdoms and counteracts translational repression of HIV-1. Proc. Natl Acad. Sci. USA. 106, 605-610 (2009
49. Han L, Zhao J, Zhang X., et al. Enhanced siRNA delivery and silencing gold-chitosan nanosystem with surface chargereversal polymer assembly and good biocompatibility. ACS Nano. 6(8), 7340-7351 (2012
50. Guo S, Huang Y, Jiang Q., et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with chargereversal polyelectrolyte. ACS Nano. 4(9), 5505-5511 (2010
51. Zhao E, Zhao Z, Wang J., et al. Surface engineering of gold nanoparticles for in vitro siRNA delivery. Nanoscale. 4(16), 5102-5109 (2012
52. Cui D, Huang P, Zhang C., et al. Dendrimer-modified gold nanorods as efficient controlled gene delivery system under near-infrared light irradiation. J. Control. Release. 1, 52(Suppl. 1), e137-e139 (2011
53. Ryou SM, Kim JM, Yeom JH., et al. Gold nanoparticleassisted delivery of small, highly structured RNA into the nuclei of human cells. Biochem. Biophys. Res. Commun. 416(1-2), 178-183 (2011
54. Guo S, Huang Y, Jiang Q., et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano. 4(9), 5505-5511 (2010
55. Mukerjee A, Shankardas J, Ranjan AP., et al. Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology. 22(44), 10 (2011
56. Chen Y, Bathula SR, Yang Q., et al. Targeted nanoparticles deliver siRNA to melanoma. J. Invest. Dermatol. 130(12), 2790-2798 (2010
57. Ho JS, Ma W, Mao DY., et al. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol. Cell Biol. 25(17), 7423-7431 (2005
58. Sachdeva M, Mo YY. p53 and c-myc: how does the cell balance "yin" and "yang"? Cell Cycle. 8(9), 1303 (2009
59. Brunelle JK, Santore MT, Budinger G., et al. c-myc sensitization to oxygen deprivation-induced cell death is dependent on Bax/Bak, but is independent of p53 and hypoxia-inducible factor-1. J. Biol. Chem. 279(6), 4305-4312 (2004
60. Juin P, Hunt A, Littlewood T., et al. c-myc functionally cooperates with Bax to induce apoptosis. Mol. Cell Biol. 22(17), 6158-6169 (2002
61. Wang C, Lisanti MP, Liao DJ. Reviewing once more the c-myc and Ras collaboration: converging at the cyclin D1-CDK4 complex and challenging basic concepts of cancer biology. Cell Cycle. 10(1), 57-67 (2011
62. Kerkhoff E, Rapp UR. Cell cycle targets of Ras/Raf signalling. Oncogene. 17, 1457-1462 (1998